123 related articles for article (PubMed ID: 12553000)
1. p63 expression profile in normal and malignant prostate epithelial cells.
Davis LD; Zhang W; Merseburger A; Young D; Xu L; Rhim JS; Moul JW; Srivastava S; Sesterhenn IA
Anticancer Res; 2002; 22(6C):3819-25. PubMed ID: 12553000
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
3. p63 expression profiles in human normal and tumor tissues.
Di Como CJ; Urist MJ; Babayan I; Drobnjak M; Hedvat CV; Teruya-Feldstein J; Pohar K; Hoos A; Cordon-Cardo C
Clin Cancer Res; 2002 Feb; 8(2):494-501. PubMed ID: 11839669
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
[TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
6. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
[TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells.
Tran CP; Lin C; Yamashiro J; Reiter RE
Mol Cancer Res; 2002 Dec; 1(2):113-21. PubMed ID: 12496358
[TBL] [Abstract][Full Text] [Related]
9. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas.
Edwards PC; Bhuiya T; Kelsch RD
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 May; 97(5):613-9. PubMed ID: 15153875
[TBL] [Abstract][Full Text] [Related]
10. Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63.
O'Connell JT; Mutter GL; Cviko A; Nucci M; Quade BJ; Kozakewich HP; Neffen E; Sun D; Yang A; McKeon FD; Crum CP
Gynecol Oncol; 2001 Jan; 80(1):30-6. PubMed ID: 11136566
[TBL] [Abstract][Full Text] [Related]
11. Naked nuclei revisited: p63 Immunoexpression.
Reis-Filho JS; Albergaria A; Milanezi F; Amendoeira I; Schmitt FC
Diagn Cytopathol; 2002 Sep; 27(3):135-8. PubMed ID: 12203858
[TBL] [Abstract][Full Text] [Related]
12. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.
Koga F; Kawakami S; Fujii Y; Saito K; Ohtsuka Y; Iwai A; Ando N; Takizawa T; Kageyama Y; Kihara K
Clin Cancer Res; 2003 Nov; 9(15):5501-7. PubMed ID: 14654529
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.
Nanni S; Priolo C; Grasselli A; D'Eletto M; Merola R; Moretti F; Gallucci M; De Carli P; Sentinelli S; Cianciulli AM; Mottolese M; Carlini P; Arcelli D; Helmer-Citterich M; Gaetano C; Loda M; Pontecorvi A; Bacchetti S; Sacchi A; Farsetti A
Mol Cancer Res; 2006 Feb; 4(2):79-92. PubMed ID: 16513839
[TBL] [Abstract][Full Text] [Related]
14. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
15. Expression of p63 protein and mRNA in oral epithelial dysplasia.
Chen YK; Hsue SS; Lin LM
J Oral Pathol Med; 2005 Apr; 34(4):232-9. PubMed ID: 15752259
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
[TBL] [Abstract][Full Text] [Related]
17. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
18. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma.
Lo Muzio L; Santarelli A; Caltabiano R; Rubini C; Pieramici T; Trevisiol L; Carinci F; Leonardi R; De Lillo A; Lanzafame S; Bufo P; Piattelli A
Hum Pathol; 2005 Feb; 36(2):187-94. PubMed ID: 15754296
[TBL] [Abstract][Full Text] [Related]
19. p63 and epithelial biology.
Barbieri CE; Pietenpol JA
Exp Cell Res; 2006 Apr; 312(6):695-706. PubMed ID: 16406339
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.
Gu Y; Li H; Miki J; Kim KH; Furusato B; Sesterhenn IA; Chu WS; McLeod DG; Srivastava S; Ewing CM; Isaacs WB; Rhim JS
Exp Cell Res; 2006 Apr; 312(6):831-43. PubMed ID: 16413016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
